Temsirolimus News and Research

RSS
Temsirolimus is approved by the Food and Drug Administration (FDA) to treat advanced renal cell carcinoma (kidney cancer). Temsirolimus is also being studied in the treatment of other types of cancer. Temsirolimus is an ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

Two candidate mTOR therapy biomarkers identified in RCC

Two candidate mTOR therapy biomarkers identified in RCC

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Oral toxicity is frequent limitation of mTOR therapy

Oral toxicity is frequent limitation of mTOR therapy

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Temsirolimus effective for mRCC patients on hemodialysis

Temsirolimus effective for mRCC patients on hemodialysis

Combination of perifosine and temsirolimus shows promise against malignant glioma

Combination of perifosine and temsirolimus shows promise against malignant glioma

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Biomarker predicts temsirolimus benefit in renal cancer

Biomarker predicts temsirolimus benefit in renal cancer